Kyowa Kirin Co Ltd
TSE:4151
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2 268
3 325
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Kyowa Kirin Co Ltd
Revenue
Kyowa Kirin Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Kyowa Kirin Co Ltd
TSE:4151
|
Revenue
ÂĄ499B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
4%
|
||
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Revenue
ÂĄ4.5T
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
||
Daiichi Sankyo Co Ltd
TSE:4568
|
Revenue
ÂĄ1.8T
|
CAGR 3-Years
20%
|
CAGR 5-Years
13%
|
CAGR 10-Years
8%
|
||
Otsuka Holdings Co Ltd
TSE:4578
|
Revenue
ÂĄ2.3T
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
4%
|
||
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Revenue
ÂĄ1.1T
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
||
Astellas Pharma Inc
TSE:4503
|
Revenue
ÂĄ1.8T
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
Kyowa Kirin Co Ltd
Glance View
Kyowa Kirin Co., Ltd. stands as a notable presence in the global pharmaceutical landscape, having evolved from its roots in Japan into a significant force in medical innovation. This company, originally established from the merger of Kyowa Hakko Kogyo and Kirin Pharma, focuses on the development and commercialization of biopharmaceuticals that tackle complex medical conditions, primarily within the fields of oncology, nephrology, immunology, and neurology. With a strategy deeply rooted in research and development, Kyowa Kirin harnesses its proprietary antibody technologies and innovative approaches to deliver therapeutic solutions, fostering partnerships that expand its impact and reach. Their commitment to scientific progress is supplemented by a robust pipeline of investigational drugs, demonstrating their dedication to addressing unmet medical needs. Kyowa Kirin operates primarily on a business model that derives revenues from the successful commercialization of its pharmaceutical products. The company navigates the delicate balance between high-stakes investment in R&D and the potential high rewards that come from developing effective new treatments. By consistently bringing innovative therapies to market, they generate revenue through direct sales, collaborations, and licensing agreements within both domestic and international spheres. Additionally, their strategic alliances with biotech firms and research institutions globally enable them to enhance their R&D capabilities, ensuring a steady flow of new drugs that sustain their growth and solidify their competitive edge in the highly regulated and competitive pharmaceutical sector.
See Also
What is Kyowa Kirin Co Ltd's Revenue?
Revenue
499B
JPY
Based on the financial report for Sep 30, 2024, Kyowa Kirin Co Ltd's Revenue amounts to 499B JPY.
What is Kyowa Kirin Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
4%
Over the last year, the Revenue growth was 19%. The average annual Revenue growth rates for Kyowa Kirin Co Ltd have been 14% over the past three years , 11% over the past five years , and 4% over the past ten years .